BRPI0410920A - análogos de tiocarbonato e carbonato de 8-azaprostaglandina como agentes terapêuticos - Google Patents

análogos de tiocarbonato e carbonato de 8-azaprostaglandina como agentes terapêuticos

Info

Publication number
BRPI0410920A
BRPI0410920A BRPI0410920-1A BRPI0410920A BRPI0410920A BR PI0410920 A BRPI0410920 A BR PI0410920A BR PI0410920 A BRPI0410920 A BR PI0410920A BR PI0410920 A BRPI0410920 A BR PI0410920A
Authority
BR
Brazil
Prior art keywords
thiocarbonate
therapeutic agents
azaprostaglandin
carbonate analogues
carbonate
Prior art date
Application number
BRPI0410920-1A
Other languages
English (en)
Inventor
David W Old
Thang D Dinh
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0410920A publication Critical patent/BRPI0410920A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANáLOGOS DE TIOCARBONATO E CARBONATO DE 8-AZAPROSTAGLANDINA COMO AGENTES TERAPêUTICOS". A presente invenção refere-se a um composto representado pela fórmula geral I; onde A, Ar, X, Z, n, x, y, R e R¬ 3¬são tais como definidos na especificação.
BRPI0410920-1A 2003-06-02 2004-05-25 análogos de tiocarbonato e carbonato de 8-azaprostaglandina como agentes terapêuticos BRPI0410920A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/453,818 US6734201B1 (en) 2003-06-02 2003-06-02 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
PCT/US2004/016479 WO2004108669A1 (en) 2003-06-02 2004-05-25 8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0410920A true BRPI0410920A (pt) 2006-06-27

Family

ID=32230467

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410920-1A BRPI0410920A (pt) 2003-06-02 2004-05-25 análogos de tiocarbonato e carbonato de 8-azaprostaglandina como agentes terapêuticos

Country Status (7)

Country Link
US (3) US6734201B1 (pt)
EP (1) EP1631544A1 (pt)
JP (1) JP2006526637A (pt)
AU (1) AU2004245490A1 (pt)
BR (1) BRPI0410920A (pt)
CA (1) CA2528006A1 (pt)
WO (1) WO2004108669A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
CA2627590A1 (en) * 2005-07-04 2007-01-11 Boehringer Ingelheim International Gmbh Method for the production of quinazolinone derivatives
KR20100031725A (ko) * 2007-06-07 2010-03-24 아스텔라스세이야쿠 가부시키가이샤 피리돈 화합물
EP2509973A1 (en) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
CN1413190A (zh) 1999-12-22 2003-04-23 辉瑞产品公司 治疗骨质疏松的ep4受体选择性激动剂
DK1132086T3 (da) 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
IL155368A0 (en) 2000-11-27 2003-11-23 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
EP1408961B1 (en) 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
HU230421B1 (hu) 2001-07-23 2016-05-30 Ono Pharmaceutical Co., Ltd Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents

Also Published As

Publication number Publication date
WO2004108669A1 (en) 2004-12-16
US6812240B1 (en) 2004-11-02
US6734201B1 (en) 2004-05-11
US20050032752A1 (en) 2005-02-10
AU2004245490A1 (en) 2004-12-16
JP2006526637A (ja) 2006-11-24
CA2528006A1 (en) 2004-12-16
EP1631544A1 (en) 2006-03-08
US7005442B2 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
BR0316375A (pt) Diazinopirimidinas
IN2012DN02609A (pt)
MY147211A (en) Novel dihydropseudoerythromycin derivatives
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
PA8649401A1 (es) Analogos de anilino-pirimidina
BR0114252A (pt) Derivados de nitrosodifenilamina
BR0312695A (pt) Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
CR7017A (es) Carboxamidas como fungicidas en agricultura
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
CR7080A (es) Sales tartrato de 5,8,14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
ATE403429T1 (de) Spiropyrazol-verbindungen
HK1088013A1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
IN2012DN00758A (pt)
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität
BRPI0507915A (pt) uso de derivados de pirimidina como fungicidas agrìcolas e horticulturais
MY146622A (en) N-phenylpyrazole derivatives as pesticides
EA200702290A1 (ru) Мотилидные соединения
MXPA03009602A (es) Analogos de nociceptina.
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
BRPI0512558A (pt) compostos quìmicos
BRPI0416571A (pt) nicotinoilcarbamatos substituìdos como pesticidas
UA87903C2 (en) Herbicidal composition

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]